Mazdutide: Side Effects & Safety
Part of the Mazdutide Complete Guide
Research Peptides
Advertiser link — we may earn a commission at no extra cost to you.
Mazdutide Safety: An NMPA-Approved Dual Co-Agonist
Mazdutide (IBI362, also LY3305677) is a dual GLP-1 / glucagon receptor agonist co-developed by Eli Lilly and Innovent Biologics. Phase 3 GLORY-1 obesity data led to China NMPA approval in 2025 for weight management.[1] The compound has substantially more cumulative human safety data than survodutide or retatrutide due to the Chinese Phase 3 program.
The safety pattern is GLP-1 class-typical (GI-dominated) plus a small glucagon-component signal (mild heart rate elevation, occasional transient ALT changes). The molecule is not FDA-approved in the US and not on the July 2026 FDA Pharmacy Compounding Advisory Committee 503A bulks list agenda. US Phase 3 development is at earlier stages.
Reported Side Effects from Phase 2 & Phase 3 Trials
Pooled from Phase 2 obesity trial (Ji et al., 2023) and Phase 3 GLORY-1 trial.[1][2]
| Effect | Frequency (active arms) | Notes |
|---|---|---|
| Nausea | ~35–45% | Peaks during titration; declines with stable dosing |
| Diarrhea | ~20–25% | Mild–moderate, transient |
| Vomiting | ~15–25% | Dose-dependent |
| Decreased appetite | ~30% | Pharmacological effect, not adverse |
| Constipation | ~10–15% | From slowed gastric motility |
| Heart rate increase | +3–5 bpm | Glucagon-related; similar magnitude to survodutide |
| Mild ALT elevation | ~5%, transient | Usually self-resolves; monitor |
| Injection-site reactions | ~8–12% | Mild, transient |
| Discontinuation due to adverse events | ~6–10% | Mostly GI-driven |
No mazdutide-related deaths or unexpected serious adverse events have been reported in Phase 2 or Phase 3 trials. The China NMPA approval reflects positive overall benefit-risk in the Chinese population.
Glucagon-Component Considerations
The glucagon receptor activity differentiates mazdutide from pure GLP-1 agonists. Specific safety considerations:
- Mild heart rate increase (+3–5 bpm at therapeutic doses) — similar to survodutide, smaller than retatrutide (+5–7 bpm).
- Transient ALT elevations in roughly 5% of patients — usually mild and self-resolving. Anyone with baseline hepatic concerns should have ALT/AST monitored.
- Hepatic fat oxidation — the desired liver-protective effect, basis for ongoing MASH research.
- Glucose handling: despite the glucagon component (which raises glucose at physiological levels), the concurrent GLP-1 activity maintains glycemic control in trials. HbA1c reductions in T2D Phase 3 are comparable to other GLP-1 family drugs.
- Energy expenditure increase contributes to weight loss alongside appetite suppression.
GLP-1 Class Safety Risks (Apply to Mazdutide)
- Acute pancreatitis: class warning. Low absolute rates. Discontinue with persistent severe abdominal pain.
- Thyroid C-cell tumors: rodent C-cell hyperplasia and MTC seen across the GLP-1 class. China NMPA approval includes precautionary contraindication for personal/family history of MTC or MEN 2.
- Gallbladder events: increased gallstone risk with rapid weight loss.
- Acute kidney injury: typically secondary to severe nausea/vomiting/dehydration.
- Hypoglycemia: uncommon with monotherapy in non-diabetics; rises with insulin or sulfonylurea combinations.
- Diabetic retinopathy: theoretical class effect from rapid HbA1c lowering.
- Gastroparesis: emerging class signal in post-market data; reasonable to assume for mazdutide.
Contraindications & Drug Interactions
- Personal or family history of medullary thyroid carcinoma or MEN 2: contraindicated.
- Severe gastrointestinal disease (gastroparesis, IBD active flare, recurrent pancreatitis): avoid.
- Type 1 diabetes: not approved; not for primary glucose management.
- Severe hepatic impairment (Child-Pugh C): caution; data limited.
- Severe renal impairment: not fully characterized.
- Pregnancy: contraindicated.
- Breastfeeding: insufficient data; avoid.
- Active malignancy: discuss with oncology.
- Known hypersensitivity to mazdutide or formulation excipients.
Drug interactions
- Insulin / sulfonylureas: reduce dose to avoid hypoglycemia.
- Oral medications (oral contraceptives, levothyroxine, warfarin, narrow-therapeutic-index drugs): delayed gastric emptying alters absorption. Monitor.
- Other GLP-1 family drugs (semaglutide, tirzepatide, retatrutide, survodutide, liraglutide): do not combine.
- Drugs affecting liver enzymes: monitor ALT during therapy.
What to Do If You Experience Side Effects
- Mild GI symptoms during titration: hold at current dose 2–4 extra weeks before next escalation. Eat smaller meals, avoid high-fat foods, hydrate.
- Severe persistent abdominal pain: stop and evaluate for pancreatitis (lipase, imaging).
- New onset palpitations or exercise intolerance: stop and seek cardiac evaluation.
- Persistent vomiting / dehydration: hold doses, restore volume, evaluate for gastroparesis.
- Elevated liver enzymes: usually transient; monitor with repeat labs. Discontinue if ALT > 3× upper limit of normal or persistent symptoms.
- Right upper quadrant pain, jaundice: evaluate for gallbladder disease.
- Allergic reaction: discontinue immediately and seek emergency care.
See the mazdutide complete guide, dosage protocols, benefits and research, and the complete GLP-1 guide.